JPRN-UMIN000030533已完成2 期
Phase II trial on Programmed death-One inhibitor plus RadioThERapy in patients with Metastatic Mucosal Melanoma - PORTER-M3 trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Synchronous or metachronous (within 5 years) malignancies except for carcinoma in situ or mucosal tumors curatively treated with local therapy. 2) The current radiation field do not overlap the previous radiation field. 3) Active infection requiring systemic therapy. 4) Patients with immune suppression. 5) Patients with central nerve system metastases. 6) Patients with complications of autoimmune disease, histories of chronic and recurrent autoimmune disease or other diseases which require systemic steroid therapy or immune suppressor. 7) Patients received live vaccines. 8) Pregnancy, possible pregnancy or breastfeeding. 9) Psychiatric disease. 10) Patients requiring systemic steroid medication. 11) Severe pulmonary fibrosis or emphysema. 12) Patients whom principle/sub-investigator judged ineligible to participate in this study.
研究者
相似试验
招募中
2 期
Phase II trial on Programmed death-One inhibitor plus RadioThERapy in patients with Metastatic Mucosal MelanomaMelanomaJPRN-jRCT1051200028omura Motoo20
终止
2 期
A clinical research study testing olaparib, in Homologous recombination (HR) deficient metastatic breast and relapsed ovarian cancer in patients who do not have hereditary mutations in BReast CAncer susceptibility gene 1 and gene 2 (BRCA1 and BRCA2)ACTRN12617000855325niversity of Sydney22
已完成
不适用
A trial to study of treatment with a new PPI for infection of H. pylori with Clarithromycin resistanceChronic gastritis infected by H. pylori with Clarithromycin resistanceJPRN-UMIN000018595ippon Kokan Fukuyama Hospital100
已完成
1 期
A clinical trial of influenza(H1N1) vaccine (Live attenuated) in Adults.CTRI/2010/091/000008Serum Institute of India Limited50
招募中
4 期
The CORINTH Trial: Study of Checkpoint Inhibitor Pembrolizumab plus standard chemoradiation in anal cancerAnal cancer2024-515369-33-00Cardiff University3